Carbapenems As a Second Line Empirical Monotherapy in Patients with Hematological Malignances, Neutropenia and Fever

摘要

In this issue we present the results of our experience with carbapenems (imipenem and meropenem) as a second line empirical monotherapy in 116 oncohematologic patients with neutropenia and fever after the failure of the first line antibiotic therapy. Our data indicate that: a) both carbapenems are an effective second-line antibiotic monotherapy (global response 65%), b) meropenem is clinicclly better tolerated than imipenem.